ImageneBio (IMA) Cash from Operations (2020 - 2025)
ImageneBio (IMA) posted Cash from Operations of 26642000.0 for Q3 2025, down 294.46% sequentially from 6754000.0 in Q2 2025, and down 305.54% YoY from 12962000.0 in Q3 2024.
ImageneBio (IMA) Cash from Operations (2020 - 2025) Analysis & Trends
ImageneBio has reported Cash from Operations for 6 years, with the latest figure at 26642000.0 in Q3 2025.
- Quarterly Cash from Operations fell 305.54% year-over-year to 26642000.0 in Q3 2025, while the trailing twelve-month figure through Sep 2025 was 68786000.0 (down 73.43% YoY) and the FY2024 annual result came in at 46004000.0, up 42.31% from the prior year.
- Cash from Operations slipped to 26642000.0 in Q3 2025 per IMA's latest filing, from 6754000.0 in the prior quarter.
- Over five years, Cash from Operations peaked at 12962000.0 in Q3 2024 and troughed at 28160000.0 in Q4 2024.
- A 5-year average of 15828105.26 and a median of 17990000.0 in 2021 frame the typical range for Cash from Operations.
- The sharpest annual moves came in 2024 and 2025: Cash from Operations surged 164.82% in 2024, then plunged 305.54% in 2025.
- Over 5 years, Cash from Operations stood at 13368000.0 in 2021, then tumbled by 32.07% to 17655000.0 in 2022, then decreased by 23.59% to 21819000.0 in 2023, then decreased by 29.06% to 28160000.0 in 2024, then increased by 5.39% to 26642000.0 in 2025.
- According to Business Quant data, Cash from Operations over the past three periods registered 26642000.0, 6754000.0, and 7230000.0 for Q3 2025, Q2 2025, and Q1 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 326.72 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.27 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -88.83 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 728.46 Mn |
| 10 | ImageneBio | 47.79 Mn | -87.56 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -26.64 Mn |
| Sep 30, 2025 | -26.64 Mn |
| Jun 30, 2025 | -6.75 Mn |
| Jun 30, 2025 | -6.75 Mn |
| Mar 31, 2025 | -7.23 Mn |
| Mar 31, 2025 | -7.23 Mn |
| Dec 31, 2024 | -28.16 Mn |
| Dec 31, 2024 | -28.16 Mn |
| Sep 30, 2024 | 12.96 Mn |
| Sep 30, 2024 | 12.96 Mn |
| Jun 30, 2024 | -12.50 Mn |
| Jun 30, 2024 | -12.50 Mn |
| Mar 31, 2024 | -18.30 Mn |
| Mar 31, 2024 | -18.30 Mn |
| Dec 31, 2023 | -21.82 Mn |
| Dec 31, 2023 | -21.82 Mn |
| Sep 30, 2023 | -20.00 Mn |
| Sep 30, 2023 | -20.00 Mn |
| Jun 30, 2023 | -18.14 Mn |
| Jun 30, 2023 | -18.14 Mn |